Vocabria

(cabotegravir) GlaxoSmithKline limited

• Vocabria, a long-acting formulation of integrase strand transfer inhibitor, is administered as an intramuscular injection every 8 weeks. Vocabria has potent antiretroviral activity, in that very few HIV infections were observed in the Vocabria group during the injection phase of the study.³

• HIV infection risk was 88% lower in the Vocabria group, showing superiority over TDF-FTC in preventing HIV in this population.³

Reference:

3. Delany-Moretlwe et al. Lancet. 2022 May 7; 399(10337): 1779–1789.